Definium Therapeutics (DFTX) Retained Earnings (2020 - 2026)
Definium Therapeutics (DFTX) reported Retained Earnings of $824000.0 for Q1 2026, up 100.2% year-over-year from $411598.3 in Q1 2025, and down 24.06% on a QoQ basis from $1.1 million in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Retained Earnings data on file, last reported at $824000.0 in Q1 2026.
- Quarterly Retained Earnings rose 100.2% year-over-year to $824000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $824000.0 (up 100.2% YoY) and the FY2025 annual result came in at $1.1 million, up 100.27% from the prior year.
- Retained Earnings eased to $824000.0 in Q1 2026 per DFTX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.1 million in Q4 2025 and bottomed at -$532.2 million in Q3 2025.
- The 5-year median for Retained Earnings is $627000.0 (2022), against an average of -$142.6 million.
- The widest annual swing landed in 2022, when Retained Earnings soared 6654.55%; it then plunged 116391.25% in 2024.
- Tracing DFTX's Retained Earnings over 5 years: stood at $627000.0 in 2022, then tumbled by 45.3% to $343000.0 in 2023, then sank by 116391.25% to -$398.9 million in 2024, then surged by 100.27% to $1.1 million in 2025, then retreated by 24.06% to $824000.0 in 2026.
- Per Business Quant, the three latest DFTX Retained Earnings figures stand at $824000.0 (Q1 2026), $1.1 million (Q4 2025), and -$532.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 824,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 824,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | -532.20 Mn |
| Jun 30, 2025 | 807,000.00 |
| Mar 31, 2025 | -422.20 Mn |
| Dec 31, 2024 | -398.88 Mn |
| Sep 30, 2024 | 821,000.00 |
| Jun 30, 2024 | 833,000.00 |
| Mar 31, 2024 | -344.60 Mn |
| Dec 31, 2023 | 343,000.00 |
| Sep 30, 2023 | -266.30 Mn |
| Jun 30, 2023 | -248.41 Mn |
| Mar 31, 2023 | -219.30 Mn |
| Dec 31, 2022 | 627,000.00 |
| Sep 30, 2022 | 743,000.00 |
| Jun 30, 2022 | 850,000.00 |
| Mar 31, 2022 | 997,000.00 |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 1.17 Mn |
| Dec 31, 2020 | -44.64 Mn |
| Mar 31, 2020 | 441,000.00 |